Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker Corporation (SYK) CEO Kevin Lobo on Q2 2019 Results - Earnings Call Transcript

Stryker earnings of $1.98 per share, minus certain items, on $3.65 billion in sales beat Wall Street estimates Thursday. But Stryker stock sank in late action after the market close.

Highly Rated Medtech Stock Narrowly Tops Earnings Forecasts

Aflac

Amazon

Intel

Starbucks

Wall Street's benchmark index, the S&P 500, and tech-laden Nasdaq Composite achieved fresh all-time highs on Jul 24, buoyed by strong earnings results.

5 Large Corporates Set to Beat on Earnings in Q2 Today

Baxter

Labcorp Holdings Inc

ResMed

West Pharmaceutical Services

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

Stryker (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Stryker (SYK) Might Surprise This Earnings Season

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.

Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?

Boston Scientific

Medtronic

Varian Medical Systems

In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.

Will USTR's 25% Tariff Exemption Spell Relief for MedTech?

Intuitive Surgical

Penumbra

Neuronetics Inc

Along with issues around ongoing talcum and opioid exposure, some rivals may have been winning at the company’s expense.

5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense

President and COO of Stryker Corp (30-Year Financial, Insider Trades) Timothy J Scannell (insider trades) sold 4,666 shares of SYK on 07/16/2019 at an average price of $205.88 a share.

Stryker Corp (SYK) President and COO Timothy J Scannell Sold $960,636 of Shares

Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Stryker (SYK) Could Beat Earnings Estimates Again

Applied Materials

Fiat Chrysler

Northrop Grumman

T. Rowe Price Group

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

5 ROE Stocks to Profit as Fed-Fueled Rate Cut Hopes Soar

ABIOMED

Amgen

Bristol-Myers

Teladoc

These beaten-down healthcare stocks still have plenty of long-term potential. Here's what investors need to know about each.

5 Healthcare Stocks to Pick Up From the Wreckage

Stryker (SYK) reported earnings 30 days ago. What's next for the stock?

Stryker (SYK) Up 0.5% Since Last Earnings Report: Can It Continue?

eBay

Coca-Cola

Yandex

A month ago, there was palpable anxiety on Wall Street over first-quarter results. Everything from bad weather to a cyclical slowdown to slower tax returns had many fearing the worst.

Deutsche Bank Raises Price Targets as Q1 Earnings Come in Red Hot

Medical technology and orthopedic implant company Stryker Corporation (NYSE: SYK) reported an earnings beat Tuesday, and three sell-side analysts remain bullish on the stock.

Analysts Review Stryker's Q1: 'The Underlying Business Momentum Remains Strong'

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.

Stryker (SYK) Q1 Earnings Beat Estimates, Revenues In Line

Stryker Corp. (SYK) CEO Kevin Lobo on Q1 2019 Results - Earnings Call Transcript

Edwards Lifesciences

Medical device companies Edwards Lifesciences and Stryker topped first-quarter earnings expectations late Tuesday, though Stryker sales were just in line.

Medical Device Giants Beat Estimates On First-Quarter Earnings

Stryker is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love Stryker

Abbott Labs

Novartis

Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

Meetings with Stryker Corporation’s (NYSE: SYK) CEO inspired greater confidence in the company’s topline growth being sustainable into the foreseeable future, as well as near- and medium-term cost-saving opportunities, according to RBC Capital Markets.

News for Stryker Stock (SYK)